Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Lobe Sciences Ltd. C.LOBE

Alternate Symbol(s):  LOBEF

Lobe Sciences is a leading “BioPsychedelic” company entering clinical stage development focused on transforming psychedelic medicine to benefit patients of all ages. We are engaged in research and development using psychedelic and non-psychedelic compounds targeting the 5HT2 receptor family. Our team is made up of biotech executives who collectively have managed the development and regulatory... see more

Bullboard (CSE:LOBE)

View:
Post by AgileTraderon Feb 15, 2024 5:42pm

Looks like $LOBE has been busy in 2023

Year end financials are out and it looks like 2024 might be the year the stock runs thanks to Altemia, which is the company's first commercial product. It's a medical food for the management ...more  
Post by Betteryear2on May 17, 2023 5:20pm

Lobe Sciences Announces Commercial Distribution Agreement

May 17, 2023 08:45 AM Eastern Daylight Time VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities